Archive for the ‘Heart Issues’ Category

Young Adults Most At-Risk for Lyme Carditis

https://danielcameronmd.com/young-adults-most-at-risk-for-lyme-carditis/

YOUNG ADULTS MOST AT-RISK FOR LYME CARDITIS

young-adult-lyme-carditis

Cardiac involvement is a rare complication of Lyme disease. But it is estimated that up to 10% of patients in the U.S. with untreated Lyme disease go on to develop Lyme carditis, according to the authors of a recent study. And, young adults are most at-risk.

Lyme carditis often presents with non-specific symptoms, such as lightheadedness, syncope, dyspnea, palpitations, and chest pain, the authors explain. While an estimated 30% of patients exhibit no symptoms.

The most common clinical manifestation “is AV block, which can be acute in onset and can rapidly progress to complete heart block,” writes Carnazzo.

In their article, “Lyme disease presenting as complete heart block in a young man: Case report and review of pathogenesis,” Carnazzo et al. discuss the case of a young man with complete heart block as a complication of Lyme disease, who presented with symptoms months after several tick bites.¹

Interestingly, young adults, particularly males, are most at-risk for developing Lyme carditis, the authors point out.

“Clinical suspicion for Lyme carditis should be high for young patients with unexplained high grade heart block, particularly in Lyme disease endemic areas.”

Their case report describes a 37-year-old man who lived in northwestern Wisconsin. He presented to the emergency department with two episodes of syncope without prodromal symptoms which had occurred over a 5-day period.

“During these days, he had increasingly frequent episodes of dizziness and near-syncope,” writes Carnazzo.

“He also reported fever, chills, muscle aches, and bilateral lower extremity erythematous rash that had developed 3 weeks earlier that had resolved by the time of presentation.”

Two months before his symptoms began, the patient had removed several ticks from his left thigh and groin.

“Lyme carditis can be difficult to recognize in cases where classic signs of Lyme disease are not obvious upon patient presentation and EM rash or tick bite difficult to recall.”

An electrocardiogram (ECG) revealed complete heart block, so a temporary pacemaker was inserted.

The man was diagnosed with Lyme carditis after he tested positive for B. burgdorferi on Western blot and treated successfully with IV ceftriaxone.

After 9 days, the heart block had completely resolved.

The authors conclude:

  • “It is important for clinicians to be familiar with the presentation and treatment of this infection that is now being observed in a wider geographic distribution so as to avoid serious long-term complications…”
  • “Timely diagnosis and treatment of heart block due to Lyme carditis can lead to immediate and life-saving temporary pacing during initiation of antibiotic therapy, while avoiding unnecessary permanent pacemaker placement.”
  • “Patients presenting with AV block should be asked about possible tick exposure, history of erythema migrans rash, recent travel to a high incidence Lyme disease area and other constitutional symptoms of Lyme disease like fever, fatigue, malaise, chills, muscle and joint pain.”
References:
  1. Carnazzo MC, Scholin C, Shweta F, Calvin AD. Lyme disease presenting as complete heart block in a young man: Case report and review of pathogenesis. IDCases. 2023 May 12;32:e01799. doi: 10.1016/j.idcr.2023.e01799. PMID: 37234726; PMCID: PMC10205533.

__________________

**Comment**

Take all percentages regarding Lyme/MSIDS with a grain of salt.  In fact, they should just stop giving them.  Since testing misses a vast majority of cases (studies have shown anywhere between 50-85% are missed), throwing percentages out is mere conjecture.  Most patients are initially mis or undiagnosed and that is a fact.  Therefore, there are probably far more cases of Lyme carditis that are not even attributed to tick-borne illness.

For more:

And now that more than 70% have been “fully vaccinated” for COVID, the plot thickens as the clot-shots are known to cause a multitude of heart and other organ problems.

Unraveling Bartonella: Dr. Mozayeni

https://www.betterhealthguy.com/episode185

About My Guest

My guest for this episode is Dr. B. Robert Mozayeni.  B. Robert Mozayeni, MD is an expert in Translational Medicine, the science and art of advancing medical science safely and efficiently.  He is the Chief Medical Officer of Galaxy Diagnostics, LLC.  He is a co-founder of the Foundation for the Study of Inflammatory Diseases.  He serves as an advisor to pharmaceutical and nutraceutical companies and serves on an Institutional Review Board specializing in nutraceutical products for pain management.  He is the immediate past President of ILADS, the International Lyme and Associated Diseases Society where his goal was to advance the science of translational medicine.  In late 2019, Dr. Mozayeni launched T Lab Inc., a research and clinical laboratory engaged in research using advanced microscopy to understand better the pathogenesis of disease in inflammatory conditions associated with persistent infections.  He has research and clinical expertise with regard to autoimmune diseases and the effects of chronic infection and inflammation on vascular physiology and neurovascular conditions seen commonly with autoimmune and neurovascular diseases.  With a strong foundation in the basic sciences and evidence-based medicine, he analyzes complex medical cases using a combination of basic scientific principles and clinical experience along with the balance of the evidence base.  Dr. Mozayeni has published numerous papers on immunology and cerebrovascular blood flow hemodynamics.  He has been actively researching and publishing his work on chronic rheumatic diseases and their relationship to persistent human Bartonella spp. infection.  Of note, chronic persistent Bartonella spp. infections are strongly associated with neurovascular diseases.  Thus, Dr. Mozayeni is uniquely qualified in the combined areas of chronic persistent endovascular infections and related rheumatological and neurovascular diseases.   He has also published papers providing new insights as to a potential infectious  (Bartonella spp.) cause of osteoarthritis and also, a case of arthritis associated with hypermobility that was likely caused by Bartonella spp.

Key Takeaways
  • What advances have been observed in recent years in the realm of Bartonella?
  • What are common symptoms of Bartonella?
  • How is Bartonella transmitted?- Might Bartonella lead to autoimmunity?
  • Can Bartonella be a trigger for PANS?
  • Might Bartonella be a contributor to osteoarthritis?
  • Is there a connection between Bartonella and hypermobility or EDS?
  • Does Bartonella contribute to MS?
  • What is the connection between Bartonella and SIBO?
  • Can Bartonella act as a trigger for MCAS?
  • Is Bartonella activation observed in those with COVID?
  • What is the state of the art in Bartonella testing?
  • What is Babesia odocoilei?
  • What agents are most helpful in the treatment of Bartonella?
  • Is there a place for herbs and other natural interventions in Bartonella treatment?
  • Should pets be considered as a potential source of exposure to Bartonella?
Connect With My Guest

http://TMGMD.com

Related Resources

Article: Unraveling the Mystery of Bartonellosis

Transcript

Go to top link for transcript, video, and audio

For more:

New Federally Funded Study Which Threw Out 75% of Cases & Didn’t Stratify for Gender Admits Covid Shot Health Risk For Children

https://jamanetwork.com/journals/jamapediatrics/fullarticle/2805184

Abstract

Importance  Active monitoring of health outcomes after COVID-19 vaccination offers early detection of rare outcomes that may not be identified in prelicensure trials.

Objective  To conduct near–real-time monitoring of health outcomes following BNT162b2 COVID-19 vaccination in the US pediatric population aged 5 to 17 years.

Design, Setting, and Participants  This population-based study was conducted under a public health surveillance mandate from the US Food and Drug Administration. Participants aged 5 to 17 years were included if they received BNT162b2 COVID-19 vaccination through mid 2022 and had continuous enrollment in a medical health insurance plan from the start of an outcome-specific clean window until the COVID-19 vaccination. Surveillance of 20 prespecified health outcomes was conducted in near real time within a cohort of vaccinated individuals from the earliest Emergency Use Authorization date for the BNT162b2 vaccination (December 11, 2020) and was expanded as more pediatric age groups received authorization through May and June 2022. All 20 health outcomes were monitored descriptively, 13 of which additionally underwent sequential testing. For these 13 health outcomes, the increased risk of each outcome after vaccination was compared with a historical baseline with adjustments for repeated looks at the data as well as a claims processing delay. A sequential testing approach was used, which declared a safety signal when the log likelihood ratio comparing the observed rate ratio against the null hypothesis exceeded a critical value.

Exposure  Exposure was defined as receipt of a BNT162b2 COVID-19 vaccine dose. The primary analysis assessed primary series doses together (dose 1 + dose 2), and dose-specific secondary analyses were conducted. Follow-up time was censored for death, disenrollment, end of the outcome-specific risk window, end of the study period, or a receipt of a subsequent vaccine dose.

Main Outcomes  Twenty prespecified health outcomes: 13 were assessed using sequential testing and 7 were monitored descriptively because of a lack of historical comparator data.

Results  This study included 3 017 352 enrollees aged 5 to 17 years. Of the enrollees across all 3 databases, 1 510 817 (50.1%) were males, 1 506 499 (49.9%) were females, and 2 867 436 (95.0%) lived in an urban area. In the primary sequential analyses, a safety signal was observed only for myocarditis or pericarditis after primary series vaccination with BNT162b2 in the age group 12 to 17 years across all 3 databases. No safety signals were observed for the 12 other outcomes assessed using sequential testing.

Conclusions and Relevance  Among 20 health outcomes that were monitored in near real time, a safety signal was identified for only myocarditis or pericarditis. Consistent with other published reports, these results provide additional evidence that COVID-19 vaccines are safe in children.

_______________

**Comment**

Please notice the strategic use of the word only.  Sorry but myocarditis and pericarditis are not small matters.  To suggest that it is normal for young people to go through life with a heart condition is truly abominable and demonstrates perfectly tyranny of the past three years. Dr. McCullough writes that myocarditis is not recovered in 80% at 6 months after the gene therapy injections.

________________

https://popularrationalism.substack.com/p/jama-study-by-us-fda-reports

JAMA STUDY BY US FDA REPORTS RECORD-BREAKING 50-FOLD INCREASED RISK OF MYOCARDITIS, 10-FOLD INCREASED RISK IN 5-11, SAYS IT “ONLY” FINDS MYOCARDITIS AND PERICARDITIS IN CHILDREN AGED 15 TO 17 YEARS

They did not stratify the results by gender and dropped 75% of the records due to lack of medical records. RRs reported? 5.50, 3.95, 10.19, 3.47, 10.26, 22.44, 8.72, 3.49, 18.65, 4.98, 10.29, 50.01.

MAY 26, 2023

Safety of the BNT162b2 COVID-19 Vaccine in Children Aged 5 to 17 Years | Pediatrics | JAMA Pediatrics | JAMA Network

One of the authors of the study is from the US Food and Drug Administration.

Dropping the 75% without medical records no doubt reduced the statistical power, the same trick used by the infamous Destefano et al study (2004) to make the association between on-time MMR vaccines and autism go away after rigorous p-hacking.

These are kids. Please retweet or share somewhere, wherever you hang out online.

(See link for article)

For more:

Many are trying to normalize heart conditions, particularly in children and babies and the timing is suspicious.

MS & COVID Gene-Therapy Shots

http://

MS and COVID Shots

May 29, 2023

Two cases of multiple sclerosis (MS), with clinical and new radiological signs, beginning in close temporal relation to spike (S) protein mRNA based vaccinations.

Conclusion

Detailed studies of both peripheral blood, and CSF derived CD4+ T cells show that the onset of MS in these two cases is very likely caused by CD4+ T cell clones that cross-recognize SARS-CoV-2 S protein derived peptides and peptides derived from myelin proteins, which have previously been implicated in MS.  Go here for John Campell’s Substack article for the sequence of events.

https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/pt/covidwho-2138820?lang=en

Covid-19 vaccination can induce multiple sclerosis via cross-reactive CD4+ T cells recognizing SARS-CoV-2 spike protein and myelin peptides

Multiple Sclerosis Journal ; 28(3 Supplement):776, 2022.
Article in English | EMBASE | ID: covidwho-2138820

“Fact-checkers” say everyone is misrepresenting this research.

Please read Walter Chesnut’s paper: The Spike Protein and SADS: Evidence of the Brainstem Demyelination/Destruction Hypothesis

SARS induced Death in mice via dysfunction of the Medulla via the OLFACTORY NERVE

I urge clinicians to perform autopsies on all those under 60 that die suddenly. We must know if the Brainstem has undergone demyelination/neuronal death. ~ Walter Chesnut

This will never happen.  Remember, Fauci ordered against autopsies on those who succumbed to COVID.  They simply don’t want to know.

Lyme Times Open Assess For May – Lyme Awareness Month

https://www.lymedisease.org/members/lyme-times/2023-summer-lymetimes/#articles

In honor of Lyme Disease Awareness Month, the latest issue of the Lyme Times is open-access–freely available to all.

This special issue offers articles from 10 prominent Lyme-treating physicians on such topics as:
  • New treatments for chronic Lyme
  • An overview of Lyme testing
  • Lyme carditis
  • Brain inflammation
  • Lyme in young children